Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
P 1 (1)
P 2 (3)

Trial Status

Unknown1
Withdrawn1
Recruiting1
Enrolling By Invitation1

Clinical Trials (4)

Showing 4 of 4 trials
NCT07114939Phase 1RecruitingPrimary

FTT PET/CT in Pancreatic Neuroendocrine Tumors

NCT05396118Phase 2Enrolling By Invitation

Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients

NCT05709171Phase 2Unknown

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

NCT04276597Phase 2Withdrawn

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

Showing all 4 trials

Research Network

Activity Timeline